Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
03 Ottobre 2024 - 11:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File No. 001-41010
MAINZ BIOMED N.V.
(Translation of registrant’s name into English)
Robert Koch Strasse 50
55129 Mainz
Germany
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form
40-F ☐
Other Events
On September 26, 2023, Mainz Biomed N.V. issued
a promissory note (the “Promissory Note”) to YA II PN, Ltd. (the “Holder”). The Promissory Note is convertible
at the Holder’s discretion into our ordinary shares at a conversion price (the “Conversion Price”) equal to the lower
of (a) $3.5424 or (b) 92% of the average of the two lowest daily volume-weighted average prices of the shares during the eight trading
days immediately prior to such conversion. The Promissory Note states that the conversion price shall not be less than a floor price of
$2.00, as may be adjusted for stock splits and other similar transactions (the “Floor Price”).
On October 2, 2024, the Company issued a conversion
notice to the Holder pursuant to which a portion of the Promissory Note will be converted into our ordinary shares. We agreed for such
conversion and any future conversions on that Promissory Note, that the Floor Price could be lowered to $0.20. As a result, we will issue
up to 2,400,000 ordinary shares in connection with the October 2, 2024 conversion.
This current report on Form 6-K is hereby
incorporated by reference into the Company’s Registration Statement on Form
F-3 (File No. 333-269091).
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 3, 2024 |
By: |
/s/ William J. Caragol |
|
Name: |
William J. Caragol |
|
Title |
Chief Financial Officer |
2
Grafico Azioni Mainz BioMed NV (NASDAQ:MYNZ)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Mainz BioMed NV (NASDAQ:MYNZ)
Storico
Da Dic 2023 a Dic 2024